40 completed, 7 unknown, 6 terminated, 5 not yet recruiting. 64 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 64 | Completed 40, Unknown 7, Terminated 6, Not yet recruiting 5, Recruiting 5, Withdrawn 1 |
Follow Tamsulosin: new trials by email Literature Review of Tamsulosin trials Research Report on Tamsulosin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial) Tamsulosin hydrochloride 0.2 mg, Placebo - Benign Prostatic Hyperplasia | Phase 4 | Not yet recruiting | Shanghai East Hospital | 400 | 2026-12-01 | 2026-09-29 |
| Uroselective Alpha-1-Antagonist to Reduce the Incidence and Duration of Postoperative Urinary Retention Following Spine Surgery Uroselective alpha-1-adrenergic receptor antagonist, Placebo - Urinary Retention Postoperative | Phase 4 | Recruiting | Mayo Clinic | 20 | 2026-10-01 | 2026-06-29 |
| Pupil Size and Choroidal Thickness Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Silodosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Iris Structural Changes With Tamsulosin vs. Silodosin in Benign Prostatic Hyperplasia Patients tamsulosin 0.4mg, Silodosin 8 mg - Benign Prostatic Hyperplasia, Tamsulosin | Phase 4 | Not yet recruiting | Mohsen Pourazizi | 40 | 2026-08-01 | 2026-08-03 |
| Tamsulosin Dose Escalation or Silodosin Switch Before Trial Without Catheter in BPH-Related Acute Urinary Retention Tamsulosin 0.4 mg, Tamsulosin 0.8 mg, Silodosin 8 mg - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 378 | 2026-06-08 | 2026-06-16 |
| Tamsulosin With or Without Tadalafil for Trial Without Catheter After Acute Urinary Retention Due to Benign Prostatic Hyperplasia Tamsulosin, Tadalafil, Tadalafil Placebo - Acute Urinary Retention, Benign Prostatic Hyperplasia | Phase 4 | Recruiting | Beni-Suef University | 320 | 2026-06-08 | 2026-06-17 |
| Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial Silodosin, Tamsulosin - Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | Phase 4 | Not yet recruiting | Ain Shams University | 140 | 2026-03-22 | 2026-03-16 |
| Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion Mirabegron, Tamsulosin - Ureteral Calculi | Phase 4 | Recruiting | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 500 | 2026-02-13 | 2026-10-01 |
| Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy Tamsulosin 0.2mg - Acute Urinary Retention, LUTS(Lower Urinary Tract Symptoms) | Phase 4 | Not yet recruiting | Peking University First Hospital | 1844 | 2026-02-01 | 2025-12-23 |
| A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate Tamsulosin Hydrochloride Sustained-Release Capsules, Lingze Tablets - Benign Prostatic Hyperplasia, Nocturia Associated With Nocturnal Polyuria | Phase 4 | Recruiting | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | 136 | 2024-12-01 | 2026-01-22 |
| Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi Tamsulosin Oral Capsule - Ureteric Stone of Lower Third of Ureter | Phase 4 | Completed | Getz Pharma | 240 | 2024-09-01 | 2025-08-20 |
| Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ. Tamsulosin, solifenacin - Ureteral Stent-Related Symptom, Alpha Blocker | Phase 4 | Completed | Liaquat National Hospital & Medical College | 60 | 2024-06-13 | 2025-08-11 |
| L-Arginine Role for Stone Lower Ureter : A Randomized Control Study NSAID, L-Arginine, 500 Mg Oral Capsule, Tamsulosin 0.4 mg QD - Stone Lower Ureter | Phase 4 | Completed | Sohag University | 153 | 2023-07-01 | 2024-12-31 |
| Medication Facilitated Ureteral Access Sheath Deployment During Ureteroscopy: The Impact of One Week of Preoperative Tamsulosin Tamsulosin 0.4 MG, Control - Urolithiasis, Tamsulosin | Phase 4 | Completed | Singapore General Hospital | 111 | 2023-06-01 | 2026-09-29 |
| Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients With Prostate Volumes ≤ 40 ml: A Prospective Comparative Study Tamsulosin 0.4 mg, Tadalafil 5mg, Tamsulosin and Tadalafil - BPH With Other Lower Urinary Tract Symptoms | Phase 4 | Completed | Fayoum University Hospital | 95 | 2023-04-20 | 2025-02-05 |
| The Efficacy and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Silodosin Capsules, Tamsulosin - Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms | Phase 4 | Completed | Xintian Pharmaceutical | 110 | 2022-09-21 | 2026-09-09 |
| THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTS Mirabegron 50 MG - Ureteral Stone, Kidney Stones | Phase 4 | Completed | Hasanuddin University | 42 | 2022-07-01 | 2023-11-13 |
| Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH UroLift System, Tamsulosin Hydrochloride - BPH | Phase 4 | Unknown | NeoTract, Inc. | 250 | 2021-12-06 | 2023-04-25 |
| Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia. Mirabegron, Tamsulosin - Overactive Bladder, Benign Prostatic Hyperplasia | Phase 4 | Unknown | St. Joseph's Healthcare Hamilton | 200 | 2021-12-01 | 2021-03-19 |
| Efficacy of Tadalafil/Solifenacin VS Tamsulosin/Solifenacin Combination Therapy for BPH/OAB Tadalafil 5mg, Tamsulosin Hcl 0.4 mg, solifenacin 10 mg - Benign Prostatic Hyperplasia, Overactive Bladder | Phase 4 | Unknown | Mansoura University | 60 | 2021-11-08 | 2022-08-10 |
Showing 20 of 64. Sign in to see all of them.
Prostatic Hyperplasia (28) · Lower Urinary Tract Symptoms (11) · Urinary Bladder, Overactive (7) · Urinary Retention (4) · Kidney Calculi (3) · Nephrolithiasis (3) · Ureteral Calculi (3) · Ureterolithiasis (3) · Urolithiasis (3) · Iris Diseases (2) · Renal Colic (2) · Urinary Incontinence (2) · Calculi (1) · Choroid Diseases (1) · Coronary Artery Disease (1)
Astellas Pharma Inc (3) · Beni-Suef University (3) · Boehringer Ingelheim (3) · GlaxoSmithKline (3) · Mansoura University (3) · Xintian Pharmaceutical (3) · Mohsen Pourazizi (2) · Samsung Medical Center (2) · Ain Shams University (1) · Albert Einstein Healthcare Network (1) · Anand Rughani, MD (1) · Andrew Meltzer (1) · Ascension Health (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Taiwan, Inc. (1)
United States (19) · Egypt (9) · South Korea (5) · China (4) · Canada (3) · France (3) · Germany (3) · Spain (3) · Greece (2) · Italy (2) · Japan (2) · Netherlands (2) · Pakistan (2) · Taiwan (2) · United Kingdom (2)
Zhongguo Chen, MD (2) · Ahmed Elhefnawy (1) · Ahmed R EL-Nahas, A. Professor (1) · Anand Rughani, MD (1) · Andrea G Lantz, MD (1) · Andrew C Meltzer, MD (1) · Andrey Z Vinarov, PhD (1) · Angel D Valdez-Vargas, MD (1) · Anil Kapoor, MD, FRCSC (1) · Benjmain N Breyer, MD, MAS (1) · Claus Roehrborn, M.D. (1)
PMID 16465187, PMID 17105794, PMID 21789068, PMID 23170127, PMID 25613154, PMID 26453222, PMID 27890522, PMID 28029383, PMID 29044968, PMID 29394114, PMID 29913020, PMID 31148056, PMID 31961963, PMID 32558340, PMID 33213185, PMID 33245533, PMID 35685573, PMID 41415574, PMID 42406401
2015 (1), K12DK111028 (1), U01DK071603 (1), U01DK096037 (1), U34DK090957 (1)